Comparative Genomics in the Enterobacteriaceae
肠杆菌科的比较基因组学
基本信息
- 批准号:6782535
- 负责人:
- 金额:$ 67.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-01 至 2007-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The number of available genome sequences
from the bacterial family Enterobacteriaceae is reaching a threshold where
comparative genomics can drive hypotheses and experiments. In this project we
have selected genomes for sequencing based on their pathogenicity and their
taxonomic position. These sequences will help us understand these and other
related pathogens by defining their differences and similarities in gene
content. (1) The genome sequences of S. enterica serovar Paratyphi A (SPA),
already sampled to 97 percent coverage, will be completed and annotated. SPA is
the second most prevalent cause of typhoid and, like S. enterica serovar Typhi
(STY), is restricted to humans. Typhi is undergoing genome degradation, perhaps
associated with its recent adaptation to a narrow host range; we will determine
if Paratyphi A is undergoing similar degradation. Klebsiella pneumoniae is a
major opportunistic pathogen. We have sequenced this genome to 8-fold coverage;
it will be closed, finished and annotated. (2) Cost-effective four-fold
sampling (97 percent coverage) will be performed for four genomes: a biotype of
S. enterica Paratyphi B (SPB), which is the third most prevalent cause of
typhoid and is host-adapted to man; S. enterica Arizonae (SAR), the most
distantly related S. enterica that regularly causes disease in humans;
Citrobacter koseri (CKO) and Enterobacter cloacae (ECL) both of which are
opportunistic pathogens representing the unsequenced genera within or adjacent
to the E. coli/Salmonella/Klebsiella clade. Web-based analysis tools that take
into account the incomplete nature of the samples will be used to present these
data in comparison to other related genomes. Finally, (3) we have amplified and
arrayed the complete open reading frames of nearly every CDS in S. enterica
subspecies 1, serovar Typhimurium LT2. This resource will be supplemented with
new putative CDSs, not found in STM, as these sequences become available from
STY, SPA, SPB, and other serovars of S. enterica. Thus, we will develop an
array that can be used in a wide variety of Salmonella, both sequenced and
unsequenced, for analysis of expression and of genome content.
描述(由申请人提供):可用基因组序列的数量
肠杆菌科细菌的数量达到了一个临界点,
比较基因组学可以推动假说和实验。在这个项目中,我们
已经根据它们的致病性和它们的
分类位置这些序列将帮助我们理解这些和其他
通过定义它们在基因上的差异和相似性,
内容(1)序列分析表明,S.甲型副伤寒(SPA),
已经抽样到97%的覆盖率,将完成和注释。SPA是
伤寒的第二大流行原因,和沙门氏菌一样。伤寒
(STY)仅限于人类。也许伤寒正在经历基因组退化
与其最近适应一个狭窄的主机范围;我们将确定
如果甲型副伤寒也在经历类似的降解肺炎克雷伯氏菌是一种
主要的机会致病菌我们已经对这个基因组进行了8倍覆盖的测序;
它将被关闭,完成和注释。(2)高性价比的四重
将对四个基因组进行采样(97%的覆盖率):
S.肠道副伤寒B(SP B),这是第三个最普遍的原因,
伤寒沙门氏菌(S. enterica Arizonae(SAR),
远房亲戚S.经常导致人类疾病的肠道菌;
科氏柠檬酸杆菌(CKO)和阴沟肠杆菌(ECL),两者均为
机会致病菌代表未测序的属内或邻近
去急诊大肠杆菌/沙门氏菌/克雷伯氏菌分支。基于Web的分析工具,
考虑到样本的不完整性,将使用这些样本来呈现这些
与其他相关基因组相比。最后,(3)我们放大了,
排列了S中几乎每个CDS的完整开放阅读框架。enterica
亚种1,鼠伤寒血清型LT 2。这一资源将得到补充,
新的推定CDS,在STM中未发现,因为这些序列可从
STY、SPA、SPB等血清型。肠因此,我们将开发一个
阵列,可用于各种沙门氏菌,测序和
未测序的,用于分析表达和基因组内容。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sandra W. Clifton其他文献
Sandra W. Clifton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sandra W. Clifton', 18)}}的其他基金
相似国自然基金
肠杆菌Klebsiella pneumoniae衍生的LPS通过肝脏HADHA-K353乙酰化修饰加剧MASLD合并T2DM疾病进程的机制研究
- 批准号:2025JJ60788
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
固氮菌Klebsiella pneumoniae NF-613厌氧还原去除造纸废水中氯代烃的机理研究
- 批准号:52200082
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
粗甘油耐受菌Klebsiella pneumoniae 2e甘油脱水酶的酶学特性与表达调控机制研究
- 批准号:2020JJ5974
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
Klebsiella pneumoniae 2e甘油脱水酶高耐受粗甘油的分子机制研究
- 批准号:31900087
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
聚羟基丁酸途径增强Klebsiella pneumoniae抗逆性机理研究
- 批准号:21106078
- 批准年份:2011
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Investigation of Klebsiella pneumoniae virulence factors and discovery of new antimicrobial agents for its infection
肺炎克雷伯菌毒力因子的研究及治疗其感染的新型抗菌药物的发现
- 批准号:
24K19861 - 财政年份:2024
- 资助金额:
$ 67.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanisms of Klebsiella pneumoniae gastrointestinal colonization
肺炎克雷伯菌胃肠道定植机制
- 批准号:
10736879 - 财政年份:2023
- 资助金额:
$ 67.02万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 67.02万 - 项目类别:
Immune recognition of Klebsiella pneumoniae O2v1 and O2v2 O-antigen subtypes
肺炎克雷伯菌 O2v1 和 O2v2 O 抗原亚型的免疫识别
- 批准号:
10739041 - 财政年份:2023
- 资助金额:
$ 67.02万 - 项目类别:
Genomic characterisation of multidrug-resistant septicaemia-causing Klebsiella pneumoniae to inform patient care and infection control
引起多重耐药败血症的肺炎克雷伯菌的基因组特征可为患者护理和感染控制提供信息
- 批准号:
2893013 - 财政年份:2023
- 资助金额:
$ 67.02万 - 项目类别:
Studentship
Optimization, Manufacturing and Testing of a Lead Therapeutic Bacteriophage Cocktail for the Treatment of Antibiotic-Resistant Klebsiella pneumoniae Infections
用于治疗耐抗生素肺炎克雷伯菌感染的先导治疗噬菌体混合物的优化、制造和测试
- 批准号:
10674294 - 财政年份:2023
- 资助金额:
$ 67.02万 - 项目类别:
Role of B cells in controlling Klebsiella pneumoniae associated disease states
B 细胞在控制肺炎克雷伯菌相关疾病状态中的作用
- 批准号:
10731411 - 财政年份:2023
- 资助金额:
$ 67.02万 - 项目类别:
Defining the systems-level impact of iron limitation in Klebsiella pneumoniae
定义肺炎克雷伯菌铁限制的系统级影响
- 批准号:
RGPIN-2020-04838 - 财政年份:2022
- 资助金额:
$ 67.02万 - 项目类别:
Discovery Grants Program - Individual
Antibiotic resistance among hypermutator carbapenem resistant Klebsiella pneumoniae
超突变碳青霉烯类耐药肺炎克雷伯菌的抗生素耐药性
- 批准号:
10650872 - 财政年份:2022
- 资助金额:
$ 67.02万 - 项目类别:
Heme-mediated STAT1 Dysfunction in Macrophages During Klebsiella pneumoniae Lung Infection
肺炎克雷伯菌肺部感染期间巨噬细胞中血红素介导的 STAT1 功能障碍
- 批准号:
10534918 - 财政年份:2022
- 资助金额:
$ 67.02万 - 项目类别: